A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Recruiting

• Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
• Interventions: Drug: zolbetuximab

• Registration Number: NCT06902545
• Lead Sponsor: Astellas Pharma Korea, Inc.

Brief Summary

This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body.

In South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein.

The main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-24
• Study First Submitted QC: 2025-03-24
• Study First Posted: 2025-03-30
• Status Verified: 2025-04
• Study Start: 2025-04-03
• Last Update Submitted: 2025-04-30
• Last Update Posted: 2025-05-01
• Primary Completion: 2030-07-31
• Study Completion: 2030-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 377

Inclusion Criteria

• Patients who receive treatment with VYLOY injection, according to the approved local label.

Exclusion Criteria

• Patients with any contraindication for VYLOY injection, according to the approved local label.
• Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Vyloy	zolbetuximab	Patients who receive treatment with Vyloy injection 100 mg (zolbetuximab), according to the approved local label.

Primary Outcome Measures

Name	Time	Method
Number of patients with an adverse drug reaction (ADR)	Up to 54 Weeks after the first administration of VYLOY	An ADR is defined as any noxious and unintended response associated with the use of a drug in humans, at any dose, where a causal relationship is at least a reasonable possibility.
Number of patients with a serious ADR (SADR)	Up to 54 Weeks after the first administration of VYLOY	An ADR considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, requires hospitalization or prolongation to hospitalization results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect, or other medically important event.
Number of patients with an unexpected AE (UAE)	Up to 54 Weeks after the first administration of VYLOY	An UAE is an AE that the nature or severity of which is not consistent with the information in the Precautions in Use Section of approved Korean label.
Number of patients with an unexpected ADR (UADR)	Up to 54 Weeks after the first administration of VYLOY	An UADR is defined as an unexpected adverse drug reaction.
Number of patients who died during the study	Up to 54 Weeks after the first administration of VYLOY
Number patients with an AE leading to death	Up to 54 Weeks after the first administration of VYLOY
Number of patients with a serious AE (SAE)	Up to 54 Weeks after the first administration of VYLOY	An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, requires hospitalization or prolongation to hospitalization results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect, or other medically important event.
Number of patients with an adverse event (AE)	Up to 54 Weeks after the first administration of VYLOY	Adverse events (AEs) will be coded using MedDRA. An AE is defined as any untoward medical occurrence in a patient administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.
Number of patients with an important risk compared to number of patients evaluated	Up to 54 Weeks after the first administration of VYLOY	An important risk is classified as an important identified risk and an important potential risk.; An identified risk is defined as the risk that correspond to undesirable clinical outcomes, with sufficient scientific evidence that the undesirable clinical outcome is caused by the drug. "Important Identified Risks" are identified risks that have the potential to affect the risk-benefit balance of a product.; An potential risk is defined as the risk that correspond to undesirable clinical outcomes, with some, but not sufficient, evidence to estimate that the undesirable clinical outcome is caused by the drug. "Important Potential Risks" are potential risks that have the potential to affect the risk-benefit balance of a product.

Secondary Outcome Measures

Name	Time	Method
Progression free survival (PFS)	Up to 54 Weeks after the first administration of VYLOY	PFS is defined as time from start of VYLOY to progressive disease (PD) or death from any cause, whichever occurs first.

Trial Locations

Locations (1)

KR82001; 🇰🇷 Seoul, Korea, Republic of